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Michele Yamamoto1,2 and Aurora E Pop-Vicas1,2*Abstract
The global spread of carbapenem-resistant
Enterobacteriaceae (CRE) is increasingly becoming a
major challenge in clinical and public health settings.
To date, the treatment for serious CRE infections
remains difficult. The intelligent use of antimicrobials
and effective infection control strategies is crucial to
prevent further CRE spread. Early consultation with
experts in the treatment of infections with multidrug-
resistant organisms is valuable in patient management.
This brief review will focus on the current, yet limited,
treatment options for CRE infections.randomized controlled trials are published on this topic.
Since carbapenem-producing organisms are often resist-Review
Introduction
The global spread of carbapenem-resistant Enterobacteria-
ceae (CRE) has become a major challenge in clinical and
public health settings. Infections with CRE organisms that
are multidrug-resistant (that is, non-susceptible to at least
one antimicrobial in at least three antimicrobial classes),
extensively drug-resistant (that is, non-susceptible to at
least one antimicrobial from all but one or two anti-
microbial classes), or pan-drug-resistant (that is, non-
susceptible to all antimicrobial agents) are difficult to treat
[1]. As a result, severe infections with CRE have significant
morbidity, mortality, and health-care costs [2-4]. Most
CRE have beta-lactamases belonging to the Ambler class
A, B, and D [5]. Table 1 summarizes main examples from
each class of carbapenemase-producing organisms.
Carbapenems are no longer fully effective in the CRE epi-
demic. The paucity of novel antimicrobials in development
escalates the antimicrobial resistance problem, severely* Correspondence: aurora_pop-vicas@brown.edu
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2014reducing the available therapeutic choices. In this review, we
will summarize the main treatment options used in clinical
practice as well as the few antimicrobials currently in devel-
opment. For issues related to the epidemiology, detection,
and prevention of infections with CRE, the reader is referred
to several excellent reviews published on this topic [6,10].Current treatment options for infections with
carbapenem-resistant Enterobacteriaceae
The optimal treatment of infections with CRE is uncer-
tain, as most data come from retrospective case series
and anecdotal case reports; few prospective studies or
ant to other antimicrobial classes in addition to most
beta-lactams, additional susceptibility testing to antimi-
crobials such as colistin, fosfomycin, tigecycline, aztreo-
nam, and rifampin is needed [11,12]. Consultations from
experts in the treatment of infections with multidrug-
resistant organisms may also prove valuable in patient
management. The following antimicrobial therapies have
been used with various levels of success in the treatment
of CRE infections.Colistin (polymyxin E)
Colistin (polymyxin E) is an old bactericidal antibiotic
with cationic detergent properties. It disrupts the outer
cell membrane of the Gram-negative bacilli by binding to
the lipid A component of the lipopolysaccharide, causing
leakage of cytoplasmic contents and bacterial cell death
[13]. The antibacterial spectrum includes most of the En-
terobacteriaceae (Escherichia coli, Klebsiella, Salmonella,
Shigella, and Enterobacter), Pseudomonas, Acinetobacter,
and Stenotrophomonas species. However, colistin is not
active against Burkholderia cepacia, Serratia marcescens,
Moraxella catarrhalis, pathogenic Neisseria spp, Proteus
spp, Providencia spp, or Morganella morganii [14].Med Central Ltd. The licensee has exclusive rights to distribute this article, in
lication. After this time, the article is available under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,










First isolated in US in 1996; now endemic in US, Colombia,
Brazil, Argentina, Poland, Italy, Greece, Israel, and China [6]





First isolated in Sweden from a traveler previously hospitalized
in New Delhi; large environmental reservoirs in India, Pakistan,
Middle East, and the Balkans [8]; recent ERCP-related nosoco-
mial outbreak associated with infected endoscopes reported
in Chicago, IL [9]
Plasmids carry resistance genes to all beta-
lactams, aminoglycosides, macrolides, rifampin,
and trimethoprim- sulfamethoxazole [8]
D
OXA-48 K. pneumoniae First identified in Turkey in 2003; multiple nosocomial
outbreaks reported since then throughout the world [7]
All beta-lactams
ERCP, endoscopic retrograde cholangiopancreatography; KPC, Klebsiella pneumoniae carbapenemase; NDM, New Delhi metallo-beta-lactamase;
OXA, oxacillin-hydrolyzing.
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aerobic Gram-positive cocci.
The ideal dose for colistin in the treatment of severe
CRE infections is uncertain. In addition, significant con-
fusion may arise because of differences in formulations
between the intravenous (IV) product available in the
US (colistin-based) and the one available in Europe and
other regions (colistimethate sodium) (Table 2). Recent
studies suggest that higher treatment doses [15] or an
initial loading dose followed by higher maintenance dos-
ing regimens may be needed for improved clinical out-
comes, especially for infections with organisms with
high minimum inhibitory concentrations (MICs) [16].
Specifically, for organisms with a colistin MIC of not
more than 2 mg/L, some authors recommend a loading
dose of 2.5 mg/kg given over a 2-hour infusion, followed
by a maintenance dose of 3 mg/kg per day, based on
population pharmacokinetic studies in critically ill pa-
tients [16]. Colistin monotherapy is not recommended
for organisms with MICs to colistin of at least 4 mg/L
[16]. Dalfino and colleagues [17], in their prospective co-
hort study of 25 critically ill patients with bacteremia or
ventilator-associated pneumonia caused by CRE (Klebsiella)
and other carbapenem-resistant bacteria (Acinetobacter
and Pseudomonas), used a regimen of 9 million IU of
colistimethate sodium loading dose (270 mg colistin base),
followed by a maintenance dose of 4.5 million IU of colis-
timethate sodium (135 mg colistin base) every 12 hours in
patients with normal renal function. For patients withTable 2 Dosing recommendations for colistin-based products
Region Product typea
US Colistin base activity
(150 mg vials)
Other Colistimethate sodium
(1 and 2 million IU vials)
a30 mg colistin base activity = 1 million IU colistimethate sodium = approximately 8
function; renal adjustment is indicated for creatinine clearance of less than 50 mL/munderlying renal injury, the dosing interval was adjusted
appropriately based on their renal clearance. The clinical
cure achieved in this high-dose study was 82.1%, with a
17.8% rate of colistin-related acute kidney injury which
was reversible within 10 days of discontinuing the drug.
Of note, colistin monotherapy was administered to less
than half of the patients in this study. Most patients
received combination therapy with a carbapenem or ami-
noglycoside in addition to colistin, although only eight
Klebsiella pneumoniae isolates were susceptible to genta-
micin and none of the isolates was susceptible to carba-
penems [17]. The colistin dosing strategy used by Dalfino
and colleagues in this study of critically ill patients does
seem to validate the recommendations from recent popu-
lation pharmacokinetic analyses [18-20], suggesting that
for severe infections in ICU patients the most effective
bacterial killing is obtained with a loading dose, followed
by higher overall maintenance doses given at extended
intervals.
The importance of combination therapy is also sug-
gested by several other retrospective studies. In a cohort
of patients with bloodstream infections caused by
K. pneumoniae carbapenemase (KPC)-producing organ-
isms, none of the 14 patients treated with colistin in
combination with one or more antimicrobials (tigecyc-
line ± carbapenem ± gentamicin) died, whereas four of
the seven patients treated with colistin alone died from
their infection [21]. Similarly, colistin-polymyxin B com-
bined with carbapenem had a mortality of 12.5% (1 out ofavailable for parenteral use in critically ill patients
Dose recommended
Loading dose: 270 mg colistin base
Maintenance dose: 135 mg colistin base every 12 hours
Loading dose: 9 million IU
Maintenance dose: 4.5 million IU every 12 hours
0 mg colistimethate sodium [15,17]. These doses are based on normal renal
inute [17].
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bacteremia caused by KPC-producing K. pneumoniae
bacteremia [22]. Finally, in a large retrospective study of
125 patients with KPC-producing K. pneumoniae sepsis
from three hospitals in Italy, the combination of colistin
with tigecycline and extended-infusion meropenem (2 g
IV infused over 3 hours every 8 hours) had the lowest
mortality (13%) versus 50% mortality for those patients
receiving colistin monotherapy [23].
The most common adverse event with colistin is
nephrotoxicity, which can develop in up to half of the pa-
tients treated with high parenteral doses but which seems
to be reversible in most cases [20,24]. Reports of resist-
ance to colistin among KPC-producing K. pneumoniae
strains [25,26], though rare, are concerning, especially
for combination treatment regimens where colistin is
intended as the major active component.
Polymyxin B
Polymyxin B differs from colistin by one amino acid
[27]. In contrast to colistin, however, it is administered
as its active form and thus achieves higher plasma con-
centrations faster, making the need for a loading dose
less stringent [16]. Polymyxin B is not cleared by the
kidney and therefore does not require renal dose adjust-
ment [28]. The clinical experience with polymyxin B in
treatment of CRE infections is limited to small case
series. Bergamasco and colleagues [29], in their descrip-
tion of a KPC-producing K. pneumoniae nosocomial
outbreak among solid organ transplant patients, re-
ported a survival rate of 67% (6 out of 9) for the patients
treated with polymyxin B alone or in combination with
tigecycline or carbapenem. These patients with pneumo-
nia, bloodstream, urinary tract, or skin and soft tissue
infections were given a polymyxin B dose of 25,000 or
15,000 IU/kg for a creatinine clearance of at least
50 mL/minute or less than 50 mL/minute, respectively.
As is true for colistin, polymyxin B used in combination
therapy for severe infections may be more effective, es-
pecially when one considers the possibility of resistance
development during monotherapy. In this regard, Lee
and colleagues [30] described the emergence of resist-
ance to polymyxin B for three out of 12 patients treated
with polymyxin B for their KPC-producing K. pneumoniae
bloodstream infections; in contrast, none of the four
patients treated with polymyxin B in combination with
tigecycline developed resistance during therapy [30].
Carbapenems
Carbapenems have been used, though counter-intuitively,
in the treatment of infections with CRE, usually as the
adjuvant component of a combination drug regimen. This
strategy is potentially useful only when the MICs of the in-
fecting carbapenem-resistant organisms are still relativelylow (that is, not more than 4 to 8 mg/L) [31]. Thus, the
MICs should always be determined and taken into ac-
count if carbapenems are contemplated as a potential
treatment option. Bacterial killing for isolates with MICs
of 4 mg/L is more likely with high-dose, prolonged-
infusion regimens (that is, meropenem 2 g IV infused over
3 hours every 8 hours) [32]. The outcomes of carbapenem
treatment in patients infected with multidrug-resistant
Gram-negative organisms, including CRE, as reported
anecdotally, in small case series or small retrospective
clinical studies are summarized in the excellent review by
Daikos and Markogiannakis [31]. A systematic review of
34 studies compiling a total of 298 patients treated for in-
fections with KPC or metallo-beta-lactamase-producing
K. pneumoniae found a combination regimen of at least
two active drugs, one of which was a carbapenem, to be
associated with the lowest failure rate (8%) compared with
other regimens studied [10] (Table 3). As previously
mentioned, Tumbarello and colleagues [23] found the
triple-combination regimen of colistin, tigecycline, and
meropenem to be associated with the highest odds of sur-
vival in their multicenter retrospective cohort study of 125
patients with KPC-producing K. pneumoniae bloodstream
infections. Meropenem was administered as an extended
infusion over at least 3 hours, at 2 g IV every 8 hours, with
renal adjustment as needed. However, although more than
50% of the isolates in this study were fully resistant to
meropenem (MIC of at least 16 mg/L), the vast majority
of the isolates were susceptible to colistin (88% with MICs
of not more than 2 mg/L) and tigecycline (91.2% with
MICs of not more than 2 mg/L).
Recently, a double-carbapenem combination (ertape-
nem-doripenem) has been proposed as a potential treat-
ment strategy for KPC-producing bacteria [38,39]. Data
come from in vitro experiments on a murine animal
model [38] as well as in vivo. Regarding the latter, three
patients with bacteremia or urinary tract infection (UTI)
caused by pan-resistant KPC-producing K. pneumoniae
[39] and one ICU patient with bacteremia and sepsis
caused by colistin-resistant KPC-producing K. pneumoniae
were reported to have been successfully treated with a
double-carbapenem combination [40]. Most recently,
Karaiskos and colleagues [41] reported treating 14 patients
with bacteremias and UTIs, including two patients with
septic shock caused by KPC-producing K. pneumoniae
with double-carbapenems therapy, as follows: 1 g ertape-
nem IV daily, followed 1 hour later by meropenem at 2 g
every 8 hours infused over 3 hours. All treated patients
experienced clinical and microbiological cure at 1-month
follow-up, although four patients experienced a recur-
rence of their UTI [41]. Nevertheless, since the clinical ex-
perience with this salvage therapy is still limited, concerns
for promoting further carbapenem resistance remain [33],
and the MICs of many carbapenem-producing organisms
Table 3 Treatment regimens and outcomes of various infections with carbapenemase-producing organisms reported in
the literature
Infection Pathogens Number Treatment Mortality Reference
Bacteremia KPC 125 Monotherapy 25/46 (54%) [23]
K. pneumoniae Combination therapy 27/79 (34%)
7/23 (30%)
Colistina + tigecyclineb 6/12 (50%)
2/16 (12%)Tigecycline + gentamicinc
Colistin + tigecycline +meropenemd
Bacteremia KPC 41 Monotherapy 11/19 (58%) [22]
K. pneumoniae Combination therapye 2/15 (13%)
1/5 (20%)
Colistin + carbapenem 0/3 (0%)
0/2 (0%)Tigecycline + carbapenem
Tigecycline + aminoglycoside
Trauma ICU KPC 26 Combination therapy 2/26 (8%) [33]
VAP K. pneumoniae
Bacteremia Tigecyclinef + gentamicing ± fosfomycinh
Tigecycline plus colistini ± fosfomycin
Bacteremia Acinetobacter 28 Monotherapy (colistinj) 2/5 (40%) [17]
VAP Pseudomonas Combination therapy 3/14 (21 %)
KPC K. pneumoniae Colistin + aminoglycoside
Colistin plus carbapenem
ICU KPC K. pneumoniae 11 Combination therapy 2/11 (18%) [34]
VAP ± bacteremia
UTI, wound Fosfomycink + colistin
Fosfomycin + gentamicin
Fosfomycin + piperacillin/tazobactam
ICU bacteremia KPC K. pneumoniae 48 Combination therapy 18/48 (37.5%) [35]
VAP Pseudomonas Fosfomycinl + colistin
Fosfomycin + tigecycline











aInitial loading dose, followed by 6 to 9 million IU/day; binitial loading dose followed by 100 to 200 mg/day; c4 to 5 mg/kg per day; d2 g every 8 hours infused
over at least 3 hours; evarious other combinations used infrequently; the other patient who died on combination therapy received carbapenem-fluoroquinolone;
f100 mg intravenous (IV) every 12 hours; g5 to 7 mg/kg per day; h4.5 million IU every 12 hours; i3 g IV every 8 hours; j9 million IU loading dose, followed by 4.5 mil-
lion IU every 12 hours if normal renal function; k4 g IV every 6 hours; lIV dose up to 24 g/day; mrates of microbiological cure were 88% in the aminoglycoside
group (n = 41), 64% in the polymyxin B group (n = 25), 43% in the tigecycline group (n = 21), and 36% in the no treatment group (n = 69). CRE, carbapenem-
resistant Enterobacteriaceae; KPC, Klebsiella pneumoniae carbapenemase; UTI, urinary tract infection; VAP, ventilator-associated pneumonia.
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this treatment strategy is not routinely recommended for
clinical practice at the present time.
Tigecycline
Tigecycline has been shown to have in vitro activity
against multidrug-resistant Enterobacteriaceae isolates
[42]. Tigecycline has been used in the treatment of in-
fections with CRE primarily as an adjuvant drug in com-
bination therapy (Table 3) [43-45]. However, the clinical
experience with tigecycline has been somewhat disap-
pointing, especially for severe infections such as blood-
stream infections or nosocomial pneumonias, for which
the drug does not have US Food and Drug Administra-
tion (FDA) approval. For example, Kontopidou and col-
leagues [46], in their study of 127 ICU patients with
bacteremias or ventilator-associated pneumonias caused
by carbapenem-resistant K. pneumoniae, found that pa-
tients treated with tigecycline, especially as monotherapy
(at doses of 100 to 200 mg/day), had the highest failure
rates compared with other drug combinations. Most
patients treated with tigecycline in this cohort had an
MIC of 2 μg/mL (which is the cutoff for susceptibility)
and severe infections with high Acute Physiology and
Chronic Health Evaluation II scores, which may explain
why tigecycline was ineffective [46]. Post-approval meta-
analyses have shown that tigecycline had lower cure
rates and higher mortality compared with other treat-
ment regimens in pooled randomized controlled trials of
various infectious syndromes [47-49]. When evaluated in
a randomized controlled trial of hospital-acquired pneu-
monia, tigecycline plus ceftazidime was inferior to
vancomycin and imipenem-cilastatin for the treatment
of ventilator-associated pneumonia [50]. The problem
may be related to the low plasma serum concentrations
achieved by the dose recommended by the manufacturer
(100 mg loading dose followed by a maintenance dose of
50 mg every 12 hours), which is likely ineffective against
pathogens with an MIC of between 0.4 and 1 mg/L.
Higher doses have been used in clinical practice [51]. In
fact, a recent phase 2 randomized controlled trial of pa-
tients with hospital-acquired pneumonia studied higher
doses of tigecycline (150 mg loading followed by 75 mg
every 12 hours, and 200 mg loading followed by 100 mg
maintenance dose every 12 hours) versus imipenem/
cilastatin. Clinical cure rates were the highest in the arm
with the highest dose regimen of tigecycline, whereas
the safety profile was similar to that of the lower dose
regimens [52]. Nevertheless, in 2010, the FDA added a
warning regarding the risk of increased mortality with
tigecycline treatment, especially for non-approved indica-
tions such as hospital- or ventilator-associated pneumo-
nias (found at [53]). This safety concern was upgraded to
a stronger Boxed Warning in 2013, after analysis of 10clinical trials of tigecycline use for FDA-approved indica-
tions, including trials conducted after drug approval, still
showed a higher (0.6%) risk of death for patients treated
with tigecycline versus other antimicrobials (found at [54]).
As a result, many clinicians have chosen tigecycline-based
regimens only when other therapies were not available.
The low concentration of tigecycline in the urine further
limits the use of this antimicrobial for the treatment of
UTIs. Unless more compelling evidence of improved
clinical outcomes in well-designed studies of high-dose
tigecycline becomes available, tigecycline monotherapy is
not routinely recommended for severe infections such as
bacteremia or hospital-acquired pneumonia.
Fosfomycin
Fosfomycin is another old broad-spectrum antibiotic
that inhibits bacterial cell wall synthesis and has in vitro
activity against CRE [12,55]. The oral formulation
achieves high concentrations in the urine and is usually
effective in the treatment of non-complicated UTIs [56].
The IV formulation (fosfomycin disodium) is not avail-
able in the US and other countries, although it has been
used successfully in Greece, mostly as an adjuvant drug
in combination therapies [57]. For example, a study of
11 critically ill patients with nosocomial infections
caused by KPC K. pneumoniae were treated with IV
fosfomycin (2 to 4 g every 6 hours) in combination with
colistin (n = 6), gentamicin (n = 3), and piperacillin/
tazobactam (n = 1). All patients were reported to have
good treatment-related microbiological and clinical out-
comes, while the all-cause hospital mortality was 18.2%
(two patients) [34]. The emergence of resistance to
fosfomycin during therapy for bacteremia with KPC
K. pneumoniae has been reported and is especially con-
cerning since fosfomycin was used as an adjunct in com-
bination therapy in these cases [58]. Recently, parenteral
fosfomycin administered in combination with colistin or
tigecycline was studied in a prospective observational
multicenter trial in 11 ICUs in Europe. In total, 41 pa-
tients with bacteremia or ventilator-associated pneumo-
nia caused by carbapenemase-producing K. pneumoniae
were treated with a median dose of 24 g of fosfomycin
per day for a total of 14 days. Microbiological cure was
reported in 56.5% of cases, with an all-cause 28-day
mortality of 43.5% and emergence of resistance in three
patients [35].
Antimicrobials in development
Several parenteral antimicrobial therapies are currently
under investigation for the treatment of multidrug-resistant
Gram-negative infections, including CRE. Ceftazidime-
avibactam (a new beta-lactamase inhibitor) is active against
extended-spectrum beta-lactamase-producing organisms,
some resistant Pseudomonas aeruginosa strains, and CRE
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such as New Delhi metallo-beta-lactamase and verona
integron-encoded metallo-beta-lactamase. It is currently
undergoing phase 3 studies for complicated UTI and intra-
abdominal infections [59]. Ceftaroline-avibactam, entering
phase 3 trials, is similarly active against KPC-producing
strains, but not against P. aeruginosa or other metallo-
beta-lactamase-producing organisms. Neither one of these
drugs in development has activity against Acinetobacter
species [6,59]. Imipenem in combination with another
novel beta-lactamase inhibitor, MK-7655, appears active
in vitro against serine carbapenemase-producing organ-
isms and against P. aeruginosa, but not against metallo-
carbapenemase-producing organisms or Acinetobacter
baumannii [59]. Plazomycin (ACHN-490), a new amino-
glycoside currently in development, has activity against
isolate-producing KPC enzymes and does not seem sus-
ceptible to the same resistance mechanisms present in
older aminoglycosides, although it does not have activity
against strains that harbor 16S ribosomal methylases. It
has completed phase 2 trials [60]. Biapenem/RPX7009
(Carbavance; Rempex Pharmaceuticals, Inc., San Diego,
CA, USA), a carbapenem combined with a novel boronate
inhibitor, currently in phase 1 trials, appears active in vitro
against KPC-producing organisms and other class A
carbapenemases, including resistant Pseudomonas and
Acinetobacter strains, although it is not active against class
B and D carbapenemases [6,61]. Eravacycline is a novel
tetracycline that is not susceptible to efflux resistance
mechanisms or to the protection of the ribosomal target
that renders older tetracyclines ineffective. It has in vitro
activity against KPC-producing bacteria but not against
non-fermenters [62].Conclusions
None of the antimicrobials currently in development has
activity against the entire spectrum of carbapenemase-
producing Gram-negative bacteria. The mortality associated
with the failure rates from the current salvage therapies
highlighted above is disconcerting. The treatment of
serious infections with CRE remains an enormous chal-
lenge. A concerted global commitment to the intelligent
use of antimicrobials, better antibiotic stewardship, the
implementation of effective infection control strategies, and
the development of more effective therapies are desperately
needed.Note: This article is part of a series on Antibiotic resistance in the
ICU, edited by Steven Opal. Other articles in this series can be
found at http://ccforum.com/series/antibioticresistance.Abbreviations
CRE: Carbapenem-resistant Enterobacteriaceae; FDA: US Food and Drug
Administration; IV: Intravenous; KPC: Klebsiella pneumoniae carbapenemase;
MIC: Minimum inhibitory concentration; UTI: Urinary tract infection.
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